Targeting TRAIL Death Receptors in Triple-Negative Breast Cancers: Challenges and Strategies for Cancer Therapy by Manjari Kundu, Yoshimi Endo Greer, Jennifer L. Dine, Stanley Lipkowitz

Get full text

Lack of Casein Kinase 1 Delta Promotes Genomic Instability - The Accumulation of DNA Damage and Down-Regulation of Checkpoint Kinase 1. by Yoshimi Endo Greer, Bo Gao, Yingzi Yang, Andre Nussenzweig, Jeffrey S Rubin

Get full text

Targeting Mitochondria with ClpP Agonists as a Novel Therapeutic Opportunity in Breast Cancer by Rohan Wedam, Yoshimi Endo Greer, David J. Wisniewski, Sarah Weltz, Manjari Kundu, Donna Voeller, Stanley Lipkowitz

Get full text

MEDI3039, a novel highly potent tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptor 2 agonist, causes regression of orthotopic tumors and inhibits outgro... by Yoshimi Endo Greer, Samuel F. Gilbert, Brunilde Gril, Rajesh Narwal, Danielle L. Peacock Brooks, David A. Tice, Patricia S. Steeg, Stanley Lipkowitz

Get full text

Characterization of TR‐107, a novel chemical activator of the human mitochondrial protease ClpP by Emily M. J. Fennell, Lucas J. Aponte‐Collazo, Joshua D. Wynn, Kristina Drizyte‐Miller, Elisa Leung, Yoshimi Endo Greer, Paul R. Graves, Andrew A. Iwanowicz, Hani Ashamalla, Ekhson Holmuhamedov, Henk Lang, Donald S. Karanewsky, Channing J. Der, Walid A. Houry, Stanley Lipkowitz, Edwin J. Iwanowicz, Lee M. Graves

Get full text